Literature DB >> 25823426

Fatigue in immune thrombocytopenia.

Quentin A Hill1, Adrian C Newland2.   

Abstract

Fatigue is an important aspect of health-related quality of life from the patient perspective and can have significant socio-economic consequences. It is a common feature of chronic illnesses and a significant number of both adults and children with immune thrombocytopenia (ITP) suffer from fatigue. Reliable, validated fatigue scales have been developed for use in ITP. These will facilitate future investigation of its pathogenesis and the effectiveness of intervention. Acute inflammation acts on neural and endocrine systems resulting in 'sickness behaviour', an adaptive response to infection and injury. Inflammation is also thought to cause fatigue in chronic disease and immune dysregulation in ITP appears to have a number of pro-inflammatory components. Clinicians should consider fatigue when assessing the burden of disease. Although effective ITP-directed therapy can improve fatigue, a number of fatigue-directed strategies may also need to be considered.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  aetiology; fatigue; immune thrombocytopenia; inflammation; quality of life

Mesh:

Substances:

Year:  2015        PMID: 25823426     DOI: 10.1111/bjh.13385

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

2.  Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation.

Authors:  Nasra Aboud; Fabian Depré; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2016-10-18       Impact factor: 3.747

3.  Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand.

Authors:  Fabian Depré; Nasra Aboud; Frauke Ringel; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2016-07-18       Impact factor: 3.747

Review 4.  Second-line therapies in immune thrombocytopenia.

Authors:  Rachael F Grace; Cindy Neunert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Health-Related Quality of Life and Burden of Fatigue in Chinese Patients with Immune Thrombocytopenia: A Cross-Sectional Study.

Authors:  Ran Yang; Hao Yao; Lin Lin; Jian-Min Ji; Qun Shen
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

6.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

7.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776

Review 8.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

9.  Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial.

Authors:  Julie Pell; Rosemary Greenwood; Jenny Ingram; Katherine Wale; Ian Thomas; Rebecca Kandiyali; Andrew Mumford; Andrew Dick; Catherine Bagot; Nichola Cooper; Quentin Hill; Charlotte Ann Bradbury
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

10.  [Predictors of fatigue among individuals with primary immune thrombocytopenia in China].

Authors:  Y Li; M E Lyu; Y T Hao; B Y Sun; Y T Huang; R F Fu; F Xue; X F Liu; L Zhang; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.